The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer

Hope S. Rugo, MD
Published Online: 3:20 PM, Wed July 19, 2017

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.